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Reduced mRNA expression levels of NFE2L2
are associated with poor outcome in breast
cancer patients
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Abstract
Background: The transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2; previously known as NRF2)
is a crucial regulator of the intracellular antioxidant response. It controls the expression of genes involved in the
detoxification and elimination of reactive oxidants and electrophilic agents. The role of NFE2L2 in cancer is subject
of controversial discussion, as it has been reported to have both pro-and anti-tumourigenic functions. To shed
some light on this paradox, we analysed the NFE2L2 mRNA expression levels in breast cancer and its association
with clinicopathological features and survival.
Methods: We retrospectively evaluated the NFE2L2 mRNA expression levels in tumour tissue of two independent
breast cancer patient cohorts. In the training set we analysed data from the Molecular Taxonomy of Breast Cancer
International Consortium (METABRIC). In the test set we measured the NFE2L2 mRNA expression levels in 176 breast
tumour tissues by quantitative real-time reverse transcription PCR (qRT-PCR). Group differences were analysed using
Mann–Whitney U-test, and associations between NFE2L2 mRNA expression levels and clinicopathological features
were examined by means of univariate and multivariate survival analyses. Furthermore, we compared NFE2L2 mRNA
expression levels between tumour and normal breast tissue samples by means of 108 paired samples from the The
Cancer Genome Atlas (TCGA) dataset.
Results: In the training set we identified an independent predictive value for high NFE2L2 mRNA expression levels
[HRdisease specific death 0.8 (0.6–1.0), P = 0.041; HRdeath 0.8 (0.6–1.0), P = 0.023] especially in the subgroup of oestrogen
receptor (ER) positive tumours [HRdisease specific death 0.6 (0.4–0.9), P = 0.008; HRdeath 0.6 (0.4–0.8), P = 0.001]. Similarly, we
found this association also in the test set [HRrelapse 0.4 (0.2–0.9), P = 0.031] and again, more pronounced in patients with
ER positive tumours [HRrelapse 0.2 (0.1–0.7), P = 0.012]. In addition, we observed generally lower NFE2L2 expression levels
in tumour tissues than in normal breast tissues.
Conclusion: We concluded that reduced NFE2L2 mRNA expression in tumour tissues is an independent predictor of
shortened survival in breast cancer patients.
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Background
Breast cancer is the most frequent cancer diagnosed in
women across the globe, accounting for 25 % of all can-
cer cases and with an estimated 1.7 million new cases
per year worldwide. Moreover, with 15 % of all cancer
deaths, breast cancer is still the most common cause for
cancer death in women in both developing and devel-
oped regions [1]. Further insight into the biology of
breast cancer is required and, besides that, additional
markers are needed to improve treatment efficiency and
patient outcome.
The gene nuclear factor, erythroid 2-like 2 (NFE2L2;
previously known as NRF2) encodes a basic leucine zip-
per (bZIP) transcription factor of the cap’n’collar (CNC)
family [2]. NFE2L2 regulates the expression of a subset
of genes, including phase II detoxifying enzymes, intra-
cellular redox-balancing proteins and transporters [3–6].
Under physiologic conditions, NFE2L2 is located in the
cytoplasm where it is bound by its redox-sensitive adapter
protein kelch-like erythroid cell-derived protein with CNC
homology (ECH)-associated protein 1 (KEAP1) and cullin
3 (CUL3), the core component of the E3 ubiquitin ligase,
which target NFE2L2 for constant proteasomal degrad-
ation. In response to NFE2L2 inducers such as excess of
reactive oxygen species (ROS) leading to oxidative stress
or chemopreventive compounds, KEAP1 undergoes con-
formational changes that partially disrupt the interaction
with NFE2L2. Thus, NFE2L2 is stabilized, accumulates
and translocates to the nucleus, where it dimerizes with
members of the small musculoaponeurotic fibrosarcoma
(MAF) protein family and binds to antioxidant response
elements (ARE) or MAF recognition elements (MARE) in
the promoter sequence of its target genes to initiate their
transcription [7–12].
Various groups reported increased susceptibility to
chemically induced carcinogenesis and decreased protec-
tion from metastasis in Nfe2l2-deficient mice [13–17].
Therefore, NFE2L2 has long been considered a cytopro-
tective transcription factor which is essential for the
defence against oxidative stress and activation of the
NFE2L2 pathway has been proposed as potential prevent-
ive strategy against carcinogenesis due to its function as a
master regulator of the expression of antioxidant and de-
toxifying enzymes [18, 19]. Interestingly, an increasing
number of contrasting findings is emerging, uncovering
the’dark side of NFE2L2’ [20, 21]. One research group, for
example, reported an association between high NFE2L2
expression and aggressive tumour behaviour [22]. Taken
together, it seems that NFE2L2 plays a dual role in cancer.
In the present study we investigated the predictive role
of NFE2L2 mRNA expression levels in breast cancer
patients of two independent cohorts. First, we used the
publicly available transcriptomic dataset of the Molecular
Taxonomy of Breast Cancer International Consortium
(METABRIC) with overall survival (OS) and disease-
specific survival (DSS) data of 1942 patients as training set
and second, a cohort derived from our own biobank con-
sisting of 176 breast cancer patients including OS and
relapse-free survival (RFS) data as test set.
Methods
Study design, patients and specimens
We retrospectively analysed three independent data sets:
(1) In a first step data from the publicly available
METABRIC dataset were used as training set to retro-
spectively explore NFE2L2 mRNA expression levels [23]
and their predictive association with outcome variables.
This dataset includes OS and DSS data as well as gene
expression and DNA copy number data from 1981
resected primary breast tumours. We excluded 39 patients
who showed either ductal carcinoma in situ (n = 10), un-
known histological differentiation (n = 24) or phyllodes tu-
mours (n = 5). Patients with HER2 positive breast cancer
did not receive anti-HER2 therapy. The median age at
diagnosis was 61.8 years (aged 21.9 to 96.3 years). All clin-
ical and genomic data is publicly available at the European
Genome-phenome Archive (EGAS00000000083) [23].
Patient characteristics and clinicopathological features
are summarized in Table 1A.
(2) Next we analysed the NFE2L2 mRNA expression
levels by quantitative reverse-transcription PCR (qRT-
PCR) in prospectively collected fresh frozen tumour tissue
samples from 176 patients with primary breast cancer
(aged 30.2 to 89.6; median age at diagnosis, 60.2 years)
and 10 patients with benign breast diseases (aged 19.8 to
46.0; median age at diagnosis, 37.2 years) treated at our
department (Department of Obstetrics and Gynaecol-
ogy, Medical University of Innsbruck, Austria) between
October 1990 and April 2010. All patients were moni-
tored within the outpatient follow-up program of our
department. Clinical, pathological and follow-up data
were stored in a database according to our hospital’s
privacy rules. Since the tissues used in this study are from
patients diagnosed between 1990 and 2010 not from all pa-
tients a written informed consent is available. But in ac-
cordance with the Austrian law, the study was reviewed
and approved by the Ethics committee of the Medical Uni-
versity of Innsbruck (reference number: AN2015-0228) and
it was conducted in accordance with the Declaration of
Helsinki. All samples were anonymized before analysis was
performed, to guarantee the protection of privacy.
The study was performed in concordance with the
Reporting Recommendations for Tumour Marker Prognos-
tic Studies of the National Cancer Institute (REMARK)
[24]. Tumour specimens were prepared and stored as
previously described [25]. Oestrogen receptor (ER) status
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Table 1 Association of NFE2L2 mRNA expression with clinicopathologic features
A NFE2L2 mRNA expression
log2 values
n Mean (+/− SD) P
Age < median age (61.79 years) 971 9.13 (0.56) <0.001
≥ median age (61.79 years) 971 9.04 (0.60)
Size T1 842 9.10 (0.59) 0.200
T2/3/4 1082 9.07 (0.57)
n.a. 18
LN negative 1007 9.07 (0.59) 0.213
positive 929 9.10 (0.58)
n.a. 6
Tumour grade I 163 9.18 (0.57) 0.021
II 767 9.09 (0.57)
III 947 9.07 (0.58)
n.a. 65
Histology invasive lobular 147 9.09 (0.65) 0.001
invasive ductal 1548 9.06 (0.58)
special differentiation 148 9.22 (0.54)
lobular and ductal mixed forms 90 9.22 (0.58)
only “invasive tumour” as information 9 9.27 (0.33)
MP premenopausal 428 9.15 (0.54) 0.003
postmenopausal 1503 9.06 (0.59)
n.a. 11
HER2 score 0/+ 667 9.11 (0.51) 0.041
score ++/+++ 147 9.19 (0.50)
n.a. 1128
ER neg 432 9.07 (0.58) 0.981
pos 1482 9.09 (0.58)
B NFE2L2 mRNA expression
loge values (norm. to TBP)
n Mean (+/− SD) P
Age < median age (60.2 years) 88 −0.71 (0.32) 0.519
≥ median age (60.2 years) 88 −0.69 (0.37)
Size T1 68 −0.63 (0.28) 0.045
T2/3/4 108 −0.74 (0.38)
LN negative 74 −0.70 (0.35) 0.389
positive 96 −0.71 (0.35)
n.a. 6
Tumour grade I 27 −0.71 (0.31) 0.513
II 115 −0.69 (0.34)
III 32 −0.74 (0.40)
n.a. 2
Histology invasive lobular carcinoma 22 −0.69 (0.47) 0.346
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and progesterone receptor (PR) status was identified by
immunohistochemistry (IHC).
Neoadjuvant chemotherapy was not administered to
the patients included in the study.
All patient characteristics and clinicopathological fea-
tures are summarized in Table 1B.
(3) Paired NFE2L2 gene expression data from 108 breast
cancer patients (tumour vs. normal tissue) from the publicly
available The Cancer Genome Atlas (TCGA) dataset were
used [26]. The patients ranged in age from 30.7 to 90 years
(mean 57.2 years). Thirty breast cancer patients (27.8 %) had
T1 tumours and 78 patients (72.2 %) T2-T4 tumours. Sixty
two patients (58.5 %) had positive lymph nodes. Seventy five
patients (69.4 %) had oestrogen-receptor positive tumours,
66 patients (61.1 %) progesterone receptor positive tumours
and 13 patients (12.7 %) HER2 positive tumours.
RNA isolation and mRNA expression analysis
Procedures were performed as previously described [25].
Primers and probe for NFE2L2 [GenBank: NM_006164.4] were
designed with Primer Express software, version 2.0. The reac-
tion is specific for isoforms 1, 2 and 3. Forward: 5′-AGC CCA
GCA CAT CCA GTC A-3′, Reverse: 5′-CAG TCA TCA
AAG TAC AAA GCA TCT GA-3′, TaqMan Probe: 5′-FAM-
CCA ACTACTCCC AGG TTG CCC AC-TAMRA-3′.
Primers and probe for the TATA box-binding protein
(TBP; endogenous RNA-control) were used according to
Bieche et al. [27]. All reactions were obtained from
Metabion (Planegg, Germany) and checked if they are
specific for mRNA and do not amplify genomic DNA.
Statistical analysis
The non-parametric Mann–Whitney U test was applied
in order to compare NFE2L2 mRNA expression levels
between groups.
Overall survival (OS) was defined as the time from
surgery to death from any cause or to the last clinical in-
spection, and disease-specific survival (DSS) as the time
from surgery to breast cancer specific death. Relapse-
free survival (RFS) was defined as the time from surgery
to histo-pathological confirmation of distant metastases
or regional recurrence.
Univariate Kaplan-Meier analyses and multivariate Cox
survival analyses were used to explore the association of
NFE2L2 mRNA expression levels with RFS, OS and DSS.
First, univariate Kaplan-Meier curves for tumour size,
lymph node status, grade, tumour histology, menopausal
status, HER2 and ER status, the application of chemother-
apy, radiation therapy or endocrine therapy and NFE2L2
mRNA expression were calculated using the log-rank test to
compare the survival distributions between groups. For
survival analysis, NFE2L2 mRNA expression levels were di-
chotomized into low and high using the 65th percentile
expression value, which was identified as the optimal thresh-
old in the training set using Youden’s index [28] based on a
receiver operating characteristic (ROC) curve analysis.
Second, we used a time-independent Cox-proportional
hazard approach for multivariate survival analysis to esti-
mate hazard ratios (HR) and 95 % Confidence interval (CI).
For the comparison of NFE2L2 mRNA expression in
paired samples (normal and breast cancer tissues) from 108
breast cancer patients the Wilcoxon paired-sample test was
applied. Statistical analysis was performed using SPSS stat-
istical software (version 20.0; SPSS Inc., Chicago, IL, USA).
Results
NFE2L2 mRNA expression levels and clinicopathological
features in breast cancer patients
In the training set (METABRIC dataset, consisting of
1942 patients) we identified associations between
Table 1 Association of NFE2L2 mRNA expression with clinicopathologic features (Continued)
invasive ductal carcinoma 135 −0.68 (0.30)
ductal carcinoma with specific differentiation 19 −0.83 (0.48)
MP premenopausal 48 −0.69 (0.29) 0.873
postmenopausal 128 −0.70 (0.37)
HER2 score 0/+ 133 −0.72 (0.38) 0.798
score ++/+++ 40 −0.66 (0.21)
n.a. 3
ER neg 49 −0.75 (0.41) 0.215
pos 127 −0.68 (0.32)
PR neg 59 −0.78 (0.42) 0.040
pos 117 −0.66 (0.29)
Abbreviations: LN lymph node status, MP menopausal status, HER2 human epidermal growth factor receptor 2 status, ER oestrogen receptor status, PR progesterone
receptor status; n.a, not available
p-values were calculated using non-parametric Mann–Whitney test
Bold values have a significance level of P < 0.05
(A) Training set: 1942 breast cancer patients, METABRIC data set. (B) Test set: 176 primary breast cancer patient
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NFE2L2 mRNA expression levels and the patient’s age
(P < 0.001), tumour histology (P = 0.001), menopausal
status (P = 0.003) and HER2 status (P = 0.041) (Table 1A).
But none of these findings could be validated in our test
set consisting of 176 breast tumour tissues from the local
biobank at the Department of Obstetrics and Gynaecol-
ogy, Medical University of Innsbruck (Table 1B). However,
we could observe significantly higher NFE2L2 mRNA
expression levels in smaller tumours (T1) compared to
larger ones (T2/3/4) (P = 0.045), and in progesterone re-
ceptor (PR) positive tumours (Table 1B; P = 0.040).
NFE2L2 mRNA expression levels and survival of breast
cancer patients
In the training cohort we identified the 65th percentile
regarding NFE2L2 mRNA expression levels as an opti-
mal cut-off value to discriminate between breast cancer
patients with a better DSS and those with a poorer out-
come. Univariate survival analysis of all 1942 breast can-
cer patients revealed that patients with high NFE2L2
mRNA expression levels had a better DSS (P = 0.005)
and OS (P = 0.003) in comparison to those with low
NFE2L2 mRNA expression levels (Table 2; Fig. 1a, b).
Since the NFE2L2 pathway was recently shown to be
more active in steroid receptor positive breast cancer [29],
we focused on ER status. Interestingly, we identified the
prognostically relevant association between high NFE2L2
mRNA expression levels and better DSS and OS in the
subgroup of patients with ER positive tumours (DSS: P =
0.013; OS: P = 0.004; Table 2A; Fig. 1c, d), but not in pa-
tients with ER negative tumours.
In the multivariate Cox-regression analysis high NFE2L2
mRNA expression levels have been validated as a marker
with independent, predictive value for a reduced risk for
disease specific death or death from any cause in the
whole cohort [HRdisease specific death 0.8 (0.6–1.0); P = 0.041,
HRdeath 0.8 (0.6–1.0); P = 0.023] (Table 3A) and in the ER-
positive tumour group [HRdisease specific death 0.6 (0.4–0.9);
P = 0.008, HRdeath 0.6 (0.4–0.8); P = 0.001] (Table 4A).
Validation of associations between NFE2L2 mRNA
expression levels and survival of breast cancer patients
To validate the identified association of high NFE2L2
mRNA expression levels with a favourable patient
outcome within an independent cohort we analysed
176 breast tumour tissue samples from our local bio-
bank. The ROC curves in Fig. 2 show the statistically
significant ability of NFE2L2 mRNA expression to be
used as a prognostic marker to predict the likelihood
of disease recurrence with an area under the curve
(AUC) value of 0.67 (95 % CI, 0.57 – 0.76; p = 0.001)
or of death with an AUC-value of 0.64 (95 % CI; 0.56
– 0.73). As cut-off value for the discrimination of
NFE2L2 high and low mRNA expression levels we
consistently applied the 65th percentile, as identified
by means of the training set. Additionally, we ana-
lysed the data on the basis of the often used median
value as cut-off value.
Univariate survival analysis of all 176 breast cancer
patients composing the test set using the 65th per-
centile as cut-off revealed that breast cancer patients
with high NFE2L2 mRNA expression levels had a bet-
ter RFS (P = 0.013) in comparison to those with low
NFE2L2 mRNA expression levels. However, there was
no statistically relevant difference regarding OS (Table 2B;
Fig. 3a, bs). Using the median as cut-off value, patients
with high NFE2L2 mRNA expression levels had a bet-
ter RFS (P < 0.001) and also OS (P = 0.004) compared
to those with low NFE2L2 mRNA expression levels
(Table 2B; Fig. 3c, d). The results of the subgroup ana-
lysis of 127 patients with ER positive tumours validated
those obtained from the training set for RFS and OS
for both cut-off types (65th percentile: RFS: P = 0.005;
OS: P = 0.034; median: RFS: P < 0.001; OS: P < 0.001)
(Table 2B; Fig. 4). Similar findings were observed in
the subgroup analysis of 117 patients with PR positive
tumours for RFS and OS for both cut-off types (65th
percentile: RFS: P = 0.030; OS: P = 0.035; median: RFS:
P = 0.002; OS: P = 0.008) (data not shown).
Moreover, high NFE2L2 mRNA expression levels, as
defined by the 65th percentile value, remained the
strongest independent factor for a reduced risk of re-
lapse in the Cox regression model [HRrelapse 0.4 (0.2–
0.9), P = 0.031] (Table 3B), as well as in the subgroup
of patients with ER positive tumours [HRrelapse 0.2
(0.1–0.7), P = 0.012] (Table 4B).
Applying the median value as cut-off, NFE2L2 mRNA
expression levels remained the strongest factor predict-
ing the risk for relapse and death in the whole cohort
[HRrelapse 0.3 (0.1–0.6); P = 0.001, HRdeath 0.5 (0.3–0.8);
P = 0.010] (Table 3B) as well as in the ER positive
tumour subgroup [HRrelapse 0.2 (0.1–0.5), P = 0.001;
HRdeath 0.4 (0.2–0.8), P = 0.009] (Table 4B). Similar
findings were observed for RFS in the subgroup analysis
of 117 patients with PR positive tumours [HRrelapse 0.3
(0.1–0.8); P = 0.020] (data not shown).
Comparison of NFE2L2 mRNA expression levels between
tumour and normal breast tissues
We compared NFE2L2 mRNA expression levels between
cancerous and the respective normal breast tissues from
a subgroup of 108 breast cancer patients of the TCGA
dataset. The analysis of these samples revealed that
NFE2L2 mRNA was significantly higher expressed in
normal breast tissue compared to breast tumor tissue of
the same patient (p < 0.001, Fig. 5).
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Table 2 Univariate survival analysis
A. Variable Disease specific survival Overall survival
No.Patients P No.Patients P
(died/total) (logrank-Test) (died/total) (logrank-Test)
Size T1 198/842 <0.001 307/842 <0.001
T2/3 414/1082 560/1082
LN negative 234/1007 <0.001 386/1007 <0.001
positive 383/929 488/929
Tumour grade I 27/163 <0.001 50/163 <0.001
II 208/767 315/767
III 365/947 473/947
Histology invasive lobular 48/147 <0.001 69/147 <0.001
invasive ductal 520/1548 727/1548
special differentiation 20/148 41/148
lobular and ductal mixed forms 27/90 36/90
only “invasive tumour” as information 4/9 4/9
MP premenopausal 141/428 0.877 152/428 <0.001
postmenopausal 472/1503 719/1503
HER2 neg 199/667 <0.001 287/667 <0.001
pos 61/147 73/147
ER neg 183/432 <0.001 213/432 0.001
pos 429/1482 653/1482
Chemotherapy no 433/1526 <0.001 682/1526 <0.001
yes 186/416 195/416
Radiation therapy no 265/781 0.461 396/781 0.028
yes 354/1161 481/1161
Endocrine therapy no 255/733 0.820 343/733 0.024
yes 364/1209 534/1209
NFE2L2 mRNA expression low (<65th %ile) 453/1268 0.005 641/1268 0.003
high (>65th %ile) 166/674 236/674
NFE2L2 mRNA expression in ER
pos tumours
low (<65th %ile) 318/968 0.013 485/968 0.004
high (>65th %tile) 111/514 168/514
B. Variable Relapse-free survival Overall survival
No.Patients P No.Patients P
(relapsed/total) (logrank-Test) (died/total) (logrank-Test)
Size T1 12/68 0.022 17/68 0.006
T2/3/4 37/108 56/108
LN negative 14/74 0.026 22/74 0.003
positive 33/96 47/96
Tumour grade I 3/27 0.154 15/27 0.764
II 34/115 42/115
III 12/32 15/32
Histology invasive lobular carcinoma 5/22 0.288 5/22 0.487
invasive ductal carcinoma 41/135 59/135
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Discussion
There are numerous studies reporting NFE2L2 activa-
tion in various types of cancer and other diseases (as ex-
tensively reviewed in [30–34]). However, there is only
little documented about the situation in breast cancer.
In the current study we identified a significant beneficial
role of elevated NFE2L2 mRNA expression levels in the
tumour for the survival of breast cancer patients based
on two independent cohorts in agreement with NFE2L2
acting as a tumour suppressor. This association was even
more pronounced in the subgroup of patients with ER
positive tumours.
The comparison of paired normal and cancerous
breast tissues from 108 breast cancer patients identified
a higher NFE2L2 mRNA expression in normal tissues,
what underscores its role as a tumour suppressor. It was
not analysed within this study if the downregulation of
NFE2L2 mRNA expression in breast cancer is related to
oncogenic NFE2L2 mutations. Therefore this mechan-
ism cannot be ruled out. But recently Kim et al. analysed
1145 cancer tissues from different carcinomas includ-
ing breast cancer. They detected NRF2 mutations in
oesophagus (8/70; 11.4 %), skin (1/17; 6.3 %), lung
(10/125; 8.0 %), and larynx (3/23; 13.0 %) cancers,
but not in breast cancer (0/95; 0 %) [35]. Therefore
we assume that NFE2L2 mutations do not play a
major role in breast cancer.
Due to the nature of the NFE2L2 mRNA expression
values, the figures of the two independent cohorts can
only be compared based on a relative, non-parametric
manner. Using Youden’s method in the training set the
65th percentile of NFE2L2 mRNA expression values was
found as an optimal threshold. In the validation set the
65th percentile was confirmed as significant cut-off for
relapse free survival in the univariate and the multivari-
able analysis. For the overall survival the 65th percentile
was validated only in the univariate analysis in the
subgroup of ER positive tumours. Extended additional
analysis showed a slightly better discrimination of the
median within the validation dataset, what corresponds
to the ROC-analysis indicating a continuous predictive
relevance of NFE2L2.
Since NFE2L2 is a transcription factor that is activated
as a consequence to oxidative and electrophilic stress, it
Table 2 Univariate survival analysis (Continued)
ductal carcinoma with specific
differentiation
3/19 9/19
MP premenopausal 14/48 0.970 14/48 0.032
postmenopausal 35/128 59/128
HER2 neg 36/133 0.971 51/133 0.692
pos 12/40 20/40
ER neg 20/49 0.061 26/49 0.831
pos 29/127 47/127
PR neg 24/59 0.021 32/59 0.234
pos 25/117 41/117
Chemotherapy no 18/90 0.022 35/90 0.382
yes 31/86 38/86
Radiation therapy no 14/68 0.348 33/68 0.069
yes 35/107 40/107
Endocrine therapy no 18/51 0.232 30/51 0.433
yes 31/125 43/125
NFE2L2 mRNA expression low (<65th %ile) 39/114 0.013 55/114 0.081
high (>65th %ile) 10/62 18/62
low (< median) 36/88 <0.001 48/88 0.004
high (> median) 13/88 25/88
NFE2L2 mRNA expression in ER pos tumours low (<65th %ile) 25/82 0.005 37/82 0.034
high (>65th %ile) 4/45 10/45
low (< median) 23/59 <0.001 32/59 <0.001
high (> median) 6/68 15/68
(A) Disease specific and overall survival in 1942 breast cancer patients in the METABRIC dataset. (B) Relapse-free and overall survival in 176 patients with primary
breast cancer
Bold values have a significance level of P < 0.05
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regulates the transcription of more than 100 genes
whose expression subsequently induces an antioxidant
response. Assumingly, this response might be advanta-
geous for survival of breast cancer patients. However,
high mRNA levels do not always have to result in in-
creased protein levels and thus functional effects. We
cannot exclude, whether upregulation of NFE2L2 ex-
pression is only a transcriptional (side-) effect not being
further translated into protein or not exerting any cellu-
lar functions. Nevertheless, our data indicate a predictive
relevance of NFE2L2 mRNA expression levels in breast
tumour tissue for patient survival.
Although NFE2L2 is commonly known as tumour sup-
pressor whose activation protects from cellular insults
upon oxidative or electrophilic stress and is thus anti-
tumourigenic and promotes cell survival of normal as well
as pre-malignant cells, there is accumulating evidence for
the’dark side of NFE2L2’: constitutive activation of NFE2L2
enhances survival, progression as well as chemo- and
radioresistance also in cancer cells and thus potentially act-
ing as an oncogene under certain circumstances. This dual
role of NFE2L2 is extensively discussed and there is com-
mon agreement that the arguments of both sides of this
paradox are of value and about the great importance of the
context [30, 33, 34]. As already mentioned above, there
are many reported cancer cases with high NFE2L2 ex-
pression, some of which are associated with increased
tumourigenesis [36, 37] and therapy resistance [38–43]
and a few correlated with poor survival [22, 44, 45]. In-
deed, Kawasaki et al. showed poorer OS in gastric cancer
upon high NFE2L2 protein expression, but this has not
been confirmed as an independent prognostic factor [22].
Contrasting with these observations, a recent study
demonstrated that lower NFE2L2 expression is associ-
ated with poorer outcome in cancer using datasets ob-
tained from the TCGA and GEO databases [46]. This
report is in line with our findings in breast cancer. Given
that these databases provide big data sets consisting of
several hundreds of patients, similar to the METABRIC
database we used as training set, the statistical power of
the survival analyses is high. Buffa et al. described
NFE2L2 as a predicted target of miR-144 [47] and ob-
served that patients who had tumours with low miR-144
and high NFE2L2 mRNA, but also protein expression
levels, had an improved distant relapse-free survival,
whereas the opposite expression pattern was associated
Fig. 1 Kaplan Meier survival analysis and NFE2L2 mRNA expression in the training set. (a) Disease specific survival and (b) Overall survival in 1942
breast cancer patients. (c) Disease specific survival and (d) Overall survival in oestrogen receptor positive breast tumours from 1482 patients
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with a poor outcome. This finding further supports our
hypothesis that NFE2L2 mRNA expression level might
serve as a predictive marker. However, contrary to our
observations, they have identified this association only in
50 patients with ER negative breast tumours.
Interestingly, another study describes a correlation be-
tween a more active NFE2L2 pathway and a more
favourable outcome in ER/PR positive breast cancer
compared to triple negative breast cancer [29], similar to
our results found in the ER positive subgroup of breast
cancer patients. It has been shown that oestrogen levels in
ER-positive tumours are higher than in ER-negative ones
[48]. In light of oestrogens acting as important ROS in-
ducers ER positive tumours might accelerate their antioxi-
dant response by upregulation of NFE2L2 activity to limit
their exposure to oxidative stress [49]. Wu et al. reported
Table 3 Multivariate Cox-regression survival analysis













Variable HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Size T1 vs. T2/3/4 1.5 (1.2–2.0) 0.003 1.5 (1.2–2.0) 0.002 1.5 (1.2–1.8) 0.001 1.5 (1.2–1.9) 0.001
LN neg. vs. pos. 1.7 (1.2–2.3) 0.002 1.7 (1.2–2.4) 0.001 1.5 (1.2–2.0) 0.002 1.6 (1.2–2.1) 0.001
Tumour grade I vs. II vs. III 1.4 (1.1 -1.9) 0.008 1.4 (1.1 -1.8) 0.014 1.3 (1.0 -1.6) 0.026 1.3 (1.0 -1.6) 0.043
MP pre vs. post 1.3 (0.9–1.7) 0.139 1.2 (0.9–1.7) 0.175 1.7 (1.2–2.2) <0.001 1.6 (1.2–2.1) 0.001
HER2 neg. vs. pos. 1.6 (1.2–2.2) 0.002 1.7 (1.2–2.2) 0.001 1.5 (1.1–2.0) 0.004 1.5 (1.2–2.0) 0.002
ER neg. vs. pos. 1.2 (0.8–1.8) 0.432 1.2 (0.8–1.7) 0.466 1.1 (0.8–1.6) 0.449 1.1 (0.8–1.6) 0.496
Histology 0.9 (0.7–1.2) 0.422 0.9 (0.7–1.2) 0.462 1.0 (0.8–1.2) 0.641 1.0 (0.8–1.2) 0.695
Chemotherapy no vs. yes 1.7 (1.1–2.5) 0.014 1.7 (1.1–2.5) 0.015 1.5 (1.0–2.2) 0.027 1.5 (1.0–2.2) 0.030
Radiation therapy no vs. yes 1.0 (0.7–1.3) 0.955 1.0 (0.7–1.3) 0.850 0.9 (0.7–1.1) 0.298 0.9 (0.7–1.1) 0.232




(< or > 65th %ile)
- - 0.8 (0.6–1.0) 0.041 - - 0.8 (0.6–1.0) 0.023













Variable HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Size T1 vs. T2/3/4 1.9 (0.8–4.3) 0.120 2.0 (0.9–4.5) 0.098 1.6 (0.8–3.2) 0.176 1.6 (0.8–3.2) 0.154
LN neg. vs. pos. 1.4 (0.7–2.9) 0.368 1.3 (0.6–2.7) 0.539 2.2 (1.2–4.3) 0.015 2.1 (1.1–4.1) 0.025
Tumour grade I vs. II vs. III 1.1 (0.6–2.1) 0.709 1.3 (0.7–2.5) 0.378 0.8 (0.5–1.2) 0.257 0.8 (0.5–1.4) 0.455
MP pre vs. post 1.0 (0.5–2.1) 0.892 1.1 (0.5–2.2) 0.817 2.0 (1.0–4.0) 0.044 2.0 (1.0–4.0) 0.038
HER2 neg. vs. pos. 1.0 (0.5–2.0) 0.995 1.0 (0.5–2.0) 0.995 1.3 (0.8–2.3) 0.342 1.4 (0.8–2.4) 0.292
ER neg. vs. pos. 0.5 (0.1–1.7) 0.257 0.4 (0.1–1.5) 0.177 1.0 (0.4–2.8) 0.990 0.9 (0.3–2.5) 0.824
PR neg. vs. pos. 1.0 (0.4–2.8) 0.992 1.2 (0.4–3.6) 0.726 1.0 (0.4–2.5) 0.982 1.1 (0.5–2.9) 0.782
Histology 0.7 (0.4–1.3) 0.270 0.6 (0.3–1.1) 0.107 1.2 (0.7–2.1) 0.533 1.2 (0.6–2.1) 0.659
Chemotherapy no vs. yes 1.4 (0.7–3.0) 0.366 1.3 (0.6–2.8) 0.495 0.9 (0.5–1.7) 0.831 0.9 (0.5–1.6) 0.684
Radiation therapy no vs. yes 1.6 (0.8–3.1) 0.202 1.5 (0.7–2.9) 0.277 0.8 (0.5–1.3) 0.374 0.8 (0.4–1.3) 0.308
Endocrine therapy no vs. yes 1.2 (0.5–3.0) 0.731 1.3 (0.5–3.4) 0.563 0.7 (0.3–1.5) 0.358 0.7 (0.4–1.5) 0.431
NFE2L2 mRNA expression low vs. high
(< or > 65th %ile)
- - 0.4 (0.2–0.9) 0.031 - - 0.6 (0.3–1.2) 0.135
low vs. high
(< or > median)
- - 0.3 (0.1–0.6) 0.001 - - 0.5 (0.3–0.8) 0.010
Abbreviations: LN lymph node status, MP menopausal status, HER2 human epidermal growth factor receptor 2 status, ER oestrogen receptor status, PR progesterone
receptor status, HR hazard ratio
(A) Disease specific survival and overall survival in 1942 breast cancer patients (METABRIC dataset). (B) Relapse-free survival and overall survival in 176 patients
with primary breast cancer
Bold values have a significance level of P < 0.05
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recently that oestrogen can increase Nrf2 activity
through activation of the PI3K/Akt/GSK3β pathway in
human breast cancer cells [50]. They suggested that
hormonal regulation of Nrf2 activity in breast cancer
may be an important consideration during various
stages of treatment and long-term patient care [50].
As mentioned before, recent studies have shown that
the context of NFE2L2 expression has a major influence
on whether NFE2L2 exerts tumour suppressive or onco-
genic functions. In particular, besides the health status of
a cell, the function and the impact of NFE2L2 in
tumourigenesis is also affected by: intracellular location
of NFE2L2, capability to be inhibited by KEAP1, choice
of a small MAF protein as dimerizing partner and
genetic polymorphisms leading to altered regulation of
NFE2L2 transcription [51–53]. Additionally, there are
cross talks between NFE2L2 signalling and other prom-
inent signalling pathways, such as NF-κB, p53 and
Notch1, affecting cell survival and other aspects of cell
fate as summarized in a detailed review [54]. These find-
ings add more complexity to the question, whether
NFE2L2 protects from or promotes carcinogenesis,
while explaining, at least in part, why this issue raises
conflicting results and is discussed controversially.
The strength of this study is the analysis of NFE2L2
mRNA expression levels in two independent cohorts
Table 4 Multivariate Cox-regression survival analysis in patients with ER pos. breast cancer













Variable HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Size T1 vs. T2/3/4 1.8 (1.3–2.5) 0.001 1.8 (1.3–2.5) 0.001 1.6 (1.2–2.1) 0.001 1.6 (1.2–2.2) 0.001
LN neg. vs. pos. 1.9 (1.3–2.8) 0.001 2.0 (1.3–2.9) 0.001 1.6 (1.2–2.3) 0.002 1.7 (1.3–2.4) 0.001
Tumour grade I vs. II vs. III 1.5 (1.2–2.0) 0.004 1.5 (1.1 -2.0) 0.006 1.3 (1.1 -1.7) 0.013 1.3 (1.0 -1.6) 0.024
MP pre vs. post 1.4 (0.9–2.2) 0.094 1.3 (0.9–2.1) 0.177 1.9 (1.3–2.8) 0.001 1.7 (1.2–2.6) 0.006
HER2 neg. vs. pos. 1.5 (1.0–2.3) 0.074 1.5 (1.0–2.3) 0.058 1.4 (1.0–2.0) 0.084 1.4 (1.0–2.1) 0.062
Histology 1.0 (0.7–1.3) 0.870 1.0 (0.8–1.3) 0.981 1.0 (0.8–1.2) 0.987 1.0 (0.8–1.3) 0.876
Chemotherapy no vs. yes 2.0 (1.2–3.4) 0.005 2.0 (1.2–3.4) 0.006 1.8 (1.1–2.9) 0.013 1.8 (1.1–2.9) 0.013
Radiation therapy no vs. yes 1.0 (0.7–1.4) 0.994 1.0 (0.7–1.3) 0.832 0.9 (0.7–1.1) 0.242 0.8 (0.6–1.1) 0.141
Endocrine therapy no vs. yes 0.7 (0.5–1.2) 0.192 0.8 (0.5–1.2) 0.297 0.8 (0.6–1.2) 0.237 0.9 (0.6–1.2) 0.392
NFE2L2 mRNA expression low vs. high
(< or > 65th %ile)
- - 0.6 (0.4–0.9) 0.008 - - 0.6 (0.4–0.8) 0.001













Variable HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Size T1 vs. T2/3/4 2.6 (1.0–6.9) 0.056 2.9 (1.1–8.0) 0.038 1.8 (0.8–3.9) 0.152 1.9 (0.8–4.1) 0.128
LN neg. vs. pos. 1.7 (0.7–4.6) 0.255 1.7 (0.6–4.6) 0.289 3.1 (1.3–7.3) 0.008 2.8 (1.2–6.5) 0.016
Tumour grade I vs. II vs. III 0.9 (0.4–2.4) 0.908 1.6 (0.5–4.6) 0.403 0.6 (0.3–1.2) 0.122 0.7 (0.3–1.4) 0.313
MP pre vs. post 0.6 (0.2–1.4) 0.221 0.5 (0.2–1.1) 0.086 1.1 (0.5–2.7) 0.756 1.1 (0.5–2.6) 0.778
HER2 neg. vs. pos. 0.4 (0.1–1.2) 0.107 0.4 (0.1–1.1) 0.079 0.7 (0.3–1.5) 0.338 0.7 (0.3–1.6) 0.420
Histology 1.5 (0.6–3.7) 0.375 1.1 (0.4–2.8) 0.895 2.1 (1.0–4.4) 0.039 2.2 (1.0–4.6) 0.045
Chemotherapy no vs. yes 0.9 (0.3–2.2) 0.761 0.7 (0.3–1.8) 0.484 0.7 (0.3–1.6) 0.437 0.7 (0.3–1.5) 0.296
Radiation therapy no vs. yes 1.7 (0.7–4.0) 0.250 1.5 (0.6–3.6) 0.349 0.7 (0.3–1.3) 0.209 0.7 (0.3–1.3) 0.211
Endocrine therapy no vs. yes 0.9 (0.2–3.4) 0.879 1.4 (0.4–5.6) 0.616 1.0 (0.3–2.8) 0.986 1.1 (0.4–3.2) 0.823
NFE2L2 mRNA expression low vs. high
(< or > 65th %ile)
- - 0.2 (0.1–0.7) 0.012 - - 0.5 (0.2–1.1) 0.072
low vs. high
(< or > median)
- - 0.2 (0.1–0.5) 0.001 - - 0.4 (0.2–0.8) 0.009
Abbreviations: LN lymph node status, MP menopausal status, HER2 human epidermal growth factor receptor 2 status, HR hazard ratio
(A) Disease specific and overall survival in 1482 patients (METABRIC dataset). (B) Relapse-free and overall survival in 127 patients
Bold values have a significance level of P < 0.05
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Fig. 2 Receiver operating characteristic (ROC) curve analysis and NFE2L2 mRNA expression in the test set. (a) Relapse-free survival and (b) overall
survival in 176 breast cancer patients
Fig. 3 Kaplan Meier survival analysis and NFE2L2 mRNA expression in the test set. (a) Relapse-free survival and (b) overall survival in 176 breast
cancer patients according the 65th percentile as cut-off value as identified by Youden’s index. (c) Relapse-free survival and (d) overall survival in
176 breast cancer patients according the median as cut-off value
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Fig. 4 Kaplan Meier survival analysis and NFE2L2 mRNA expression in 127 patients with oestrogen receptor positive breast cancer of the test set.
(a) Relapse-free survival and (b) overall survival according the 65th percentile as cut-off value. (c ) Relapse-free survival and (d) overall survival in
oestrogen receptor positive breast tumours from 127 patients according the median as cut-off value
Fig. 5 Analysis of paired breast tissue samples. Comparison of NFE2L2 mRNA expression levels between paired data from tumour tissue and
respective normal tissue from 108 breast cancer patients (TCGA dataset). Mean values and standard deviations are depicted in the diagram.
Outliers are indicated by circles, extreme values by asterisks. The Wilcoxon paired-sample test was applied to compute the p-value.
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consisting of 2118 patients in total. As a limitation of our
study, as already mentioned, the NFE2L2 mRNA
expression levels may not reflect the functionally active
protein levels, which could affect the interpretation of these
data; however, without repercussions on the major finding
concerning the predictive value of NFE2L2 mRNA expres-
sion. Further mRNA but also protein expression studies are
needed to validate the results of the present study.
Conclusions
In summary, in our data we identified a predictive poten-
tial of NFE2L2 mRNA expression levels in breast cancer,
especially in ER positive breast cancer, since high NFE2L2
expression was associated with better survival. Thus, de-
termination of the NFE2L2 mRNA expression level might
be clinically useful to improve the characterization of
breast cancer, eventually leading to more efficient and
personalized treatment of breast cancer patients.
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